300676 华大基因
已收盘 05-09 15:00:00
资讯
新帖
简况
华大基因新注册《病原体保守特异区域筛选软件V1.0》等4个项目的软件著作权
证券之星 · 05-01
华大基因新注册《病原体保守特异区域筛选软件V1.0》等4个项目的软件著作权
时代大考来临,华大基因(300676.SZ)的破局突围之路
格隆汇 · 04-27
时代大考来临,华大基因(300676.SZ)的破局突围之路
华大基因(300676)2025年一季报简析:净利润减524.87%,公司应收账款体量较大
证券之星 · 04-26
华大基因(300676)2025年一季报简析:净利润减524.87%,公司应收账款体量较大
图解华大基因一季报:第一季度单季净利润同比减524.87%
证券之星 · 04-26
图解华大基因一季报:第一季度单季净利润同比减524.87%
图解华大基因年报:第四季度单季净利润同比减3552.75%
证券之星 · 04-26
图解华大基因年报:第四季度单季净利润同比减3552.75%
华大基因一季度净现金流为-6826.34万元同比增长89.40%,经营性现金流为负
金融界 · 04-25
华大基因一季度净现金流为-6826.34万元同比增长89.40%,经营性现金流为负
华大基因一季度营业总支出7.09亿元,销售费用1.63亿元
金融界 · 04-25
华大基因一季度营业总支出7.09亿元,销售费用1.63亿元
【华大基因:独立董事曹亚因任期届满卸任】金融界4月26日消息,华大基因公告称,公司独立董事曹亚因第三届董事会任期届满于2024年6月18日卸任公司独立董事职务。
金融界 · 04-25
【华大基因:独立董事曹亚因任期届满卸任】金融界4月26日消息,华大基因公告称,公司独立董事曹亚因第三届董事会任期届满于2024年6月18日卸任公司独立董事职务。
【量价齐跌榜前十:泰鸿万立连续7天缩量下跌,累计跌幅30.68%】截至4月18日收盘,泰鸿万立量价齐跌,连续7天缩量下跌,累计跌幅30.68%。其余量价齐升的上涨个股还包括:新希望(缩量下跌6天)、ST天山(缩量下跌6天)、锦浪科技(缩量下跌6天)、北京文化(缩量下跌5天)、海鸥住工(缩量下跌5天)、纳思达(缩量下跌5天)、科伦药业(缩量下跌5天)、新雷能(缩量下跌5天)、华大基因(缩量下跌5天)。
金融界 · 04-18
【量价齐跌榜前十:泰鸿万立连续7天缩量下跌,累计跌幅30.68%】截至4月18日收盘,泰鸿万立量价齐跌,连续7天缩量下跌,累计跌幅30.68%。其余量价齐升的上涨个股还包括:新希望(缩量下跌6天)、ST天山(缩量下跌6天)、锦浪科技(缩量下跌6天)、北京文化(缩量下跌5天)、海鸥住工(缩量下跌5天)、纳思达(缩量下跌5天)、科伦药业(缩量下跌5天)、新雷能(缩量下跌5天)、华大基因(缩量下跌5天)。
华大基因:目前公司业务暂未涉及DNA存储及DNA计算机方面的研究
证券之星 · 03-11
华大基因:目前公司业务暂未涉及DNA存储及DNA计算机方面的研究
华大基因:截至2024年10月31日公司的普通股股东总数为65696人
证券之星 · 03-11
华大基因:截至2024年10月31日公司的普通股股东总数为65696人
华大基因:公司主营业务为基因检测等多组学大数据技术手段提供服务和解决方案
证券之星 · 03-11
华大基因:公司主营业务为基因检测等多组学大数据技术手段提供服务和解决方案
华大基因:如公司有相关资本规划,将在巨潮资讯网发布公告,及时履行信息披露义务
证券之星 · 03-11
华大基因:如公司有相关资本规划,将在巨潮资讯网发布公告,及时履行信息披露义务
诺唯赞(688105.SH)与华大基因(300676.SZ)签订战略合作协议
智通财经 · 03-07
诺唯赞(688105.SH)与华大基因(300676.SZ)签订战略合作协议
华大基因与诺唯赞签署合作协议
美港电讯 · 03-07
华大基因与诺唯赞签署合作协议
【机构调研记录】华安基金调研华大基因、阿拉丁等3只个股(附名单)
证券之星 · 03-06
【机构调研记录】华安基金调研华大基因、阿拉丁等3只个股(附名单)
【机构调研记录】光大保德信基金调研华大基因
证券之星 · 03-06
【机构调研记录】光大保德信基金调研华大基因
【机构调研记录】万家基金调研华大基因
证券之星 · 03-06
【机构调研记录】万家基金调研华大基因
华大基因:财通基金管理有限公司、太平洋资产管理有限责任公司等多家机构于3月4日调研我司
证券之星 · 03-05
华大基因:财通基金管理有限公司、太平洋资产管理有限责任公司等多家机构于3月4日调研我司
3月4日华大基因涨8.39%,万家经济新动能混合A基金重仓该股
证券之星 · 03-04
3月4日华大基因涨8.39%,万家经济新动能混合A基金重仓该股
加载失败,点击重试
公司概况
公司名称:
深圳华大基因股份有限公司
所属行业:
专业技术服务业
上市日期:
2017-07-14
主营业务:
深圳华大基因股份有限公司的主营业务为通过基因检测,质谱检测,生物信息分析等多组学大数据技术手段,为科研机构,企事业单位,医疗机构,社会卫生组织等提供研究服务和精准医学检测综合解决方案。公司主要产品包括孕期营养检测、人体氨基酸检测、人体维生素检测等。公司荣获“2022年度ESG最佳社会责任企业”、“2023医疗器械出海最佳战略布局企业”、“2022年度投资者关系金奖杰出IR公司”,“2023环境、社会及治理(ESG)年度案例”等多项社会荣誉或奖项,有效提升了公司的品牌知名度和影响力。
发行价格:
13.64
{"stockData":{"symbol":"300676","market":"SZ","secType":"STK","nameCN":"华大基因","latestPrice":48.12,"timestamp":1746774234000,"preClose":49.51,"halted":0,"volume":4339764,"delay":0,"changeRate":-0.0281,"floatShares":413999999,"shares":416000000,"eps":-2.3275,"marketStatus":"已收盘","change":-1.39,"latestTime":"05-09 15:00:00","open":49.51,"high":49.54,"low":48,"amount":211000000,"amplitude":0.0311,"askPrice":48.12,"askSize":30,"bidPrice":48.11,"bidSize":182,"shortable":0,"etf":0,"ttmEps":-2.3275,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747013400000},"marketStatusCode":5,"adr":0,"adjPreClose":49.51,"symbolType":"stock","openAndCloseTimeList":[[1746754200000,1746761400000],[1746766800000,1746774000000]],"highLimit":54.46,"lowLimit":44.56,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":415821575,"isCdr":false,"pbRate":2.26,"roa":"--","roe":"--","epsLYR":-2.189,"committee":0.747837,"marketValue":20009000000,"turnoverRate":0.0105,"status":1,"floatMarketCap":19901000000},"requestUrl":"/m/hq/s/300676/tweets","defaultTab":"tweets","newsList":[{"id":"2532720883","title":"华大基因新注册《病原体保守特异区域筛选软件V1.0》等4个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2532720883","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532720883?lang=zh_cn&edition=full","pubTime":"2025-05-02 01:17","pubTimestamp":1746119834,"startTime":"0","endTime":"0","summary":"证券之星消息,近日华大基因(300676)新注册了4个项目的软件著作权,包括《病原体保守特异区域筛选软件V1.0》、《携带者筛查自动化分析软件V1.0》、《基于扩增子测序的HBV分型检测软件V1.0》、《变异注释后处理软件V1.0》等。今年以来华大基因新注册软件著作权14个,较去年同期增加了55.56%。结合公司2024年年报财务数据,2024年公司在研发方面投入了6.06亿元,同比增14.6%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050200000154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0221","BK0046","BK0196","300676","BK0197"],"gpt_icon":0},{"id":"2530648580","title":"时代大考来临,华大基因(300676.SZ)的破局突围之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2530648580","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530648580?lang=zh_cn&edition=full","pubTime":"2025-04-27 13:23","pubTimestamp":1745731405,"startTime":"0","endTime":"0","summary":"华大基因最新披露的2024年度业绩显示,公司实现营业收入38.67亿元。行业承压寻突破,结构韧性谋新篇在行业整体承压的背景下,华大基因2024年度报告呈现出独特的结构韧性。在生育健康领域,尽管新生儿出生率持续走低,华大基因却凭借其在该领域的深厚积累与前瞻布局,展现出相对稳健的态势。同时,华大基因在肿瘤与慢病防控领域则增长显著。市场前景上来看,华大基因所布局的肿瘤基因检测领域即将迎来爆发期。华大基因给出了这样的答卷。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27132349925635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0197","BK0196","BK0046","BK0042","BK0221","300676"],"gpt_icon":0},{"id":"2530898177","title":"华大基因(300676)2025年一季报简析:净利润减524.87%,公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2530898177","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530898177?lang=zh_cn&edition=full","pubTime":"2025-04-27 06:39","pubTimestamp":1745707196,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期华大基因发布2025年一季报。截至本报告期末,公司营业总收入6.72亿元,同比下降18.18%,归母净利润-5269.51万元,同比下降524.87%。本报告期华大基因公司应收账款体量较大,当期应收账款占最新年报营业总收入比达43.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042700002044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300676"],"gpt_icon":0},{"id":"2530115821","title":"图解华大基因一季报:第一季度单季净利润同比减524.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530115821","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530115821?lang=zh_cn&edition=full","pubTime":"2025-04-26 09:35","pubTimestamp":1745631306,"startTime":"0","endTime":"0","summary":"证券之星消息,华大基因2025年一季报显示,公司主营收入6.72亿元,同比下降18.18%;归母净利润-5269.51万元,同比下降524.87%;扣非净利润-6329.71万元,同比下降2879.13%;负债率26.68%,投资收益341.62万元,财务费用-2747.41万元,毛利率43.55%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600009278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300676"],"gpt_icon":0},{"id":"2530519012","title":"图解华大基因年报:第四季度单季净利润同比减3552.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530519012","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530519012?lang=zh_cn&edition=full","pubTime":"2025-04-26 08:34","pubTimestamp":1745627692,"startTime":"0","endTime":"0","summary":"证券之星消息,华大基因2024年年报显示,公司主营收入38.67亿元,同比下降11.1%;归母净利润-9.03亿元,同比下降1071.68%;扣非净利润-9.19亿元,同比下降1090.83%;其中2024年第四季度,公司单季度主营收入10.41亿元,同比下降13.7%;单季度归母净利润-7.79亿元,同比下降3552.75%;单季度扣非净利润-7.8亿元,同比下降12668.79%;负债率26.08%,投资收益-4362.63万元,财务费用-5033.85万元,毛利率41.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600008726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300676"],"gpt_icon":0},{"id":"2530163077","title":"华大基因一季度净现金流为-6826.34万元同比增长89.40%,经营性现金流为负","url":"https://stock-news.laohu8.com/highlight/detail?id=2530163077","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530163077?lang=zh_cn&edition=full","pubTime":"2025-04-26 01:33","pubTimestamp":1745602426,"startTime":"0","endTime":"0","summary":"华大基因一季报数据显示,2025年1-3月,公司净现金流为-6826.34万元同比增长89.40%,其中,经营性现金流-3.97亿元,投资性现金流-2.22亿元,融资性现金流5.49亿元。报告期内,公司销售商品、提供劳务收到的现金为6.04亿元,取得投资收益收到的现金为2013.24万元,购建固定资产、无形资产和其他长期资产支付的现金为1.71亿元。企业注册资本4.16亿人民币,法人代表为赵立见。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/26013349901099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0042","BK0196","300676","BK0221","159399","BK0046","BK0197"],"gpt_icon":0},{"id":"2530163040","title":"华大基因一季度营业总支出7.09亿元,销售费用1.63亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530163040","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530163040?lang=zh_cn&edition=full","pubTime":"2025-04-26 01:33","pubTimestamp":1745602409,"startTime":"0","endTime":"0","summary":"华大基因一季报数据显示,2025年1-3月,公司营业总收入6.72亿元同比下滑18.18%,营业总支出7.09亿元同比下滑9.89%,其中,营业支出3.79亿元,销售费用1.63亿元,管理费用7405.81万元,财务费用-2747.41万元。营业利润-6617.38万元,同比下滑450.29%。企业注册资本4.16亿人民币,法人代表为赵立见。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/26013349901093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300676","BK0042","BK0046","BK0196","BK0221","BK0197"],"gpt_icon":0},{"id":"2530168264","title":"【华大基因:独立董事曹亚因任期届满卸任】金融界4月26日消息,华大基因公告称,公司独立董事曹亚因第三届董事会任期届满于2024年6月18日卸任公司独立董事职务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530168264","media":"金融界","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530168264?lang=zh_cn&edition=full","pubTime":"2025-04-26 01:25","pubTimestamp":1745601941,"startTime":"0","endTime":"0","summary":"金融界4月26日消息,华大基因公告称,公司独立董事曹亚因第三届董事会任期届满于2024年6月18日卸任公司独立董事职务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/26012549901037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0196","BK0042","300676","BK0221","BK0197","BK0046"],"gpt_icon":0},{"id":"2528304940","title":"【量价齐跌榜前十:泰鸿万立连续7天缩量下跌,累计跌幅30.68%】截至4月18日收盘,泰鸿万立量价齐跌,连续7天缩量下跌,累计跌幅30.68%。其余量价齐升的上涨个股还包括:新希望(缩量下跌6天)、ST天山(缩量下跌6天)、锦浪科技(缩量下跌6天)、北京文化(缩量下跌5天)、海鸥住工(缩量下跌5天)、纳思达(缩量下跌5天)、科伦药业(缩量下跌5天)、新雷能(缩量下跌5天)、华大基因(缩量下跌5天)。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528304940","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528304940?lang=zh_cn&edition=full","pubTime":"2025-04-18 16:42","pubTimestamp":1744965775,"startTime":"0","endTime":"0","summary":"截至4月18日收盘,泰鸿万立量价齐跌,连续7天缩量下跌,累计跌幅30.68%。其余量价齐升的上涨个股还包括:新希望(缩量下跌6天)、ST天山(缩量下跌6天)、锦浪科技(缩量下跌6天)、北京文化(缩量下跌5天)、海鸥住工(缩量下跌5天)、纳思达(缩量下跌5天)、科伦药业(缩量下跌5天)、新雷能(缩量下跌5天)、华大基因(缩量下跌5天)。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/18164249658223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002084","002422","BK0196","BK0093","LU1064130708.USD","603210","BK0046","300676","BK0137","BK0125","BK0186","BK0092","BK0038","BK0177","BK0077","BK0117","BK0060","LU1064131003.USD","BK0087","BK0042","300313","000876","000802","BK0214","002180","300763","BK0240","BK0238","BK0188","300593","BK0183","BK0098","BK0012","BK0197","BK0221","BK0256","BK0264","LU2148510915.USD","BK0028","BK0139","BK0267","BK0224","BK0239","BK0187"],"gpt_icon":0},{"id":"2518760634","title":"华大基因:目前公司业务暂未涉及DNA存储及DNA计算机方面的研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2518760634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518760634?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:39","pubTimestamp":1741678764,"startTime":"0","endTime":"0","summary":"证券之星消息,华大基因(300676)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,我了解到我们公司有有关DNA存储技术对吧?我还想了解一下有没有生物计算机或DNA计算机方面的研究呢?多谢华大基因回复:您好,感谢您对华大基因的关注。目前公司业务暂未涉及DNA存储及DNA计算机方面的研究。谢谢。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100022667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300676","BK0196","BK0197","BK0042","BK0221","BK0046","159998"],"gpt_icon":0},{"id":"2518750762","title":"华大基因:截至2024年10月31日公司的普通股股东总数为65696人","url":"https://stock-news.laohu8.com/highlight/detail?id=2518750762","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518750762?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:31","pubTimestamp":1741678284,"startTime":"0","endTime":"0","summary":"证券之星消息,华大基因03月11日在投资者关系平台上答复投资者关心的问题。顺祝你们,身体健康,万事如意, 【比如截至到2025年2月20日贵公司的股东人数是多少?】.华大基因回复:您好,感谢您对华大基因的关注。根据公司发布的《2024年三季度报告》,截至2024年10月31日,公司的普通股股东总数为65696人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100021819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0221","300676","BK0196","BK0042","BK0197","BK0046"],"gpt_icon":0},{"id":"2518762723","title":"华大基因:公司主营业务为基因检测等多组学大数据技术手段提供服务和解决方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2518762723","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518762723?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:31","pubTimestamp":1741678270,"startTime":"0","endTime":"0","summary":"证券之星消息,华大基因(300676)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司,有无涉及机器人业务。华大基因回复:您好,感谢您对华大基因的关注。公司主营业务为通过基因检测、质谱检测、生物信息分析等多组学大数据技术手段,为科研机构、企事业单位、医疗机构、社会卫生组织等提供研究服务和精准医学检测综合解决方案。谢谢。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100021804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0046","300676","BK0197","BK0042","159739","BK0221"],"gpt_icon":0},{"id":"2518762291","title":"华大基因:如公司有相关资本规划,将在巨潮资讯网发布公告,及时履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2518762291","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518762291?lang=zh_cn&edition=full","pubTime":"2025-03-11 15:31","pubTimestamp":1741678270,"startTime":"0","endTime":"0","summary":"证券之星消息,华大基因(300676)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问:当前鼓励上市公司对有协同性业务的公司进行并购重组,公司是否有这方面的考虑。华大基因回复:您好,感谢您对华大基因的关注。如公司有相关资本规划,将在巨潮资讯网发布公告,及时履行信息披露义务。谢谢。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100021805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0046","300676","BK0197","BK0196","BK0221"],"gpt_icon":0},{"id":"2517310414","title":"诺唯赞(688105.SH)与华大基因(300676.SZ)签订战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2517310414","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517310414?lang=zh_cn&edition=full","pubTime":"2025-03-07 17:52","pubTimestamp":1741341147,"startTime":"0","endTime":"0","summary":"智通财经APP讯,诺唯赞(688105.SH)发布公告,公司与华大基因(300676.SZ)近日于深圳市签署了《战略合作协议》,拟依托各自的专业技术、行业地位和资源优势,在生殖遗传、肿瘤防控、慢性疾病管理以及感染防控等业务方向进行战略合作。本次协议签订,双方将聚焦生命科学、体外诊断领域,旨在通过优势互补,共同推动技术创新与产品应用落地,在主动健康管理、以心脑血管疾病为代表的慢性病防控等领域加深合作,共同促进我国生物科技协同发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺唯赞(688105.SH)与华大基因(300676.SZ)签订战略合作协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0216","BK0042","BK0046","BK0221","300676","BK0197","688105"],"gpt_icon":0},{"id":"2517124464","title":"华大基因与诺唯赞签署合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2517124464","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517124464?lang=zh_cn&edition=full","pubTime":"2025-03-07 13:46","pubTimestamp":1741326395,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159837","BK0042","300152","688105","BK0196","BK0046","BK0197","BK0101","BK0147","BK0160","300676","BK0216","BK0135","BK0221","BK0218"],"gpt_icon":0},{"id":"2517976631","title":"【机构调研记录】华安基金调研华大基因、阿拉丁等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517976631?lang=zh_cn&edition=full","pubTime":"2025-03-06 08:08","pubTimestamp":1741219729,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及3月5日披露的机构调研信息,华安基金近期对3家上市公司进行了调研,相关名单如下:1)华大基因 调研纪要:华大基因已将AI技术应用于遗传病辅助诊断,显著提升了通量和效率,降低了生产成本。华安基金成立于1998年,截至目前,资产管理规模6543.08亿元,排名16/209;资产管理规模4237.56亿元,排名12/209;管理公募基金数508只,排名11/209;旗下公募基金经理73人,排名12/209。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030600006537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300676","688179","BK0196","BK0046","BK0197","BK0221","BK0216","BK0042"],"gpt_icon":0},{"id":"2517976571","title":"【机构调研记录】光大保德信基金调研华大基因","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976571","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517976571?lang=zh_cn&edition=full","pubTime":"2025-03-06 08:07","pubTimestamp":1741219626,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及3月5日披露的机构调研信息,光大保德信基金近期对1家上市公司进行了调研,相关名单如下:1)华大基因 调研纪要:华大基因已将AI技术应用于遗传病辅助诊断,显著提升了通量和效率,降低了生产成本。光大保德信基金成立于2004年,截至目前,资产管理规模757.36亿元,排名72/209;资产管理规模569.61亿元,排名67/209;管理公募基金数135只,排名53/209;旗下公募基金经理21人,排名66/209。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030600006484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0046","300676","BK0197","BK0196","BK0221"],"gpt_icon":0},{"id":"2517976620","title":"【机构调研记录】万家基金调研华大基因","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976620","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517976620?lang=zh_cn&edition=full","pubTime":"2025-03-06 08:01","pubTimestamp":1741219295,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及3月5日披露的机构调研信息,万家基金近期对1家上市公司进行了调研,相关名单如下:1)华大基因 调研纪要:华大基因已将AI技术应用于遗传病辅助诊断,显著提升了通量和效率,降低了生产成本。万家基金成立于2002年,截至目前,资产管理规模4951.74亿元,排名25/209;资产管理规模1705.08亿元,排名31/209;管理公募基金数322只,排名20/209;旗下公募基金经理42人,排名26/209。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030600006325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0221","BK0042","BK0046","300676","BK0196"],"gpt_icon":0},{"id":"2517955731","title":"华大基因:财通基金管理有限公司、太平洋资产管理有限责任公司等多家机构于3月4日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2517955731","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517955731?lang=zh_cn&edition=full","pubTime":"2025-03-05 11:30","pubTimestamp":1741145456,"startTime":"0","endTime":"0","summary":"华大基因在算力部署上有长期积累和合作伙伴关系,包括与超算中心和GPU卡供应商的合作,可以满足临时大规模训练和日常研发需求。华大基因主营业务:通过基因检测、质谱检测、生物信息分析等多组学大数据技术手段,为科研机构、企事业单位、医疗机构、社会卫生组织等提供研究服务和精准医学检测综合解决方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500016054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK1542","BK0197","BK0077","BK0188","BK1583","09983","BK0028","BK0042","BK0046","BK1229","300676","BK0201","601099","BK0183","BK0196","BK0276","BK1258","BK0221"],"gpt_icon":0},{"id":"2516964248","title":"3月4日华大基因涨8.39%,万家经济新动能混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2516964248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516964248?lang=zh_cn&edition=full","pubTime":"2025-03-04 16:26","pubTimestamp":1741076793,"startTime":"0","endTime":"0","summary":"证券之星消息,3月4日华大基因涨8.39%,收盘报65.91元,换手率5.64%,成交量23.25万手,成交额14.8亿元。3月4日的资金流向数据方面,主力资金净流入1.89亿元,占总成交额12.79%,游资资金净流入1171.42万元,占总成交额0.79%,散户资金净流出2.01亿元,占总成交额13.58%。重仓华大基因的公募基金请见下表:根据2024基金年报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为万家经济新动能混合A。该公募基金现任基金经理为黄兴亮。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030400027453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","300676","BK0042","BK0221","BK0046","BK0197"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746969583050,"stockEarnings":[{"period":"1week","weight":-0.0031},{"period":"1month","weight":-0.0048},{"period":"3month","weight":-0.0372},{"period":"6month","weight":-0.0454},{"period":"1year","weight":0.1179},{"period":"ytd","weight":0.1465}],"compareEarnings":[{"period":"1week","weight":0.0192},{"period":"1month","weight":0.0487},{"period":"3month","weight":0.0116},{"period":"6month","weight":-0.0319},{"period":"1year","weight":0.0595},{"period":"ytd","weight":-0.0029}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳华大基因股份有限公司","boardCode":"AI0074","boardName":"专业技术服务业","stockholders":"61929人(较上一季度增加0.49%)","perCapita":"6677股","listingDate":"2017-07-14","address":"广东省深圳市盐田区洪安三街21号华大综合园7栋7层-14层","registeredCapital":"41582万元","survey":" 深圳华大基因股份有限公司的主营业务为通过基因检测,质谱检测,生物信息分析等多组学大数据技术手段,为科研机构,企事业单位,医疗机构,社会卫生组织等提供研究服务和精准医学检测综合解决方案。公司主要产品包括孕期营养检测、人体氨基酸检测、人体维生素检测等。公司荣获“2022年度ESG最佳社会责任企业”、“2023医疗器械出海最佳战略布局企业”、“2022年度投资者关系金奖杰出IR公司”,“2023环境、社会及治理(ESG)年度案例”等多项社会荣誉或奖项,有效提升了公司的品牌知名度和影响力。","listedPrice":13.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华大基因(300676)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华大基因(300676)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华大基因,300676,华大基因股票,华大基因股票老虎,华大基因股票老虎国际,华大基因行情,华大基因股票行情,华大基因股价,华大基因股市,华大基因股票价格,华大基因股票交易,华大基因股票购买,华大基因股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华大基因(300676)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华大基因(300676)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}